Zymeworks has dosed the first patient in its Phase I clinical trial of ZW191, an investigational therapy, aimed at treating advanced solid tumours that express folate receptor-α (FRα).
This therapy is intended for the treatment of endometrial, ovarian and non-small cell lung (NSCLC) cancers.
ZW191 has demonstrated greater anti-tumour activity compared to standard FRα-expressing tumour models in data presented at the American Association for Cancer Research (AACR) Annual Meeting last year.
The first-in-human, two-part, multi-centre, global Phase I study is planning to enrol 145 adult patients.
Patients will be recruited from investigator sites across Europe, North America and the Asia-Pacific region.
The study’s first part will focus on the tolerability and safety of ZW191, including dose escalation in subjects with advanced endometrial, ovarian and NSCLC cancers.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSecondary endpoints will measure pharmacokinetics and the confirmed objective response rate.
The second part will assess the safety of ZW191 and explore its potential anti-tumour activity.
Zymeworks recently commenced a first-in-human Phase I trial of ZW171, targeting advanced or metastatic ovarian cancer, NSCLC, and other mesothelin (MSLN)-expressing cancers.
ZW191 is an antibody-drug conjugate specifically engineered to target FRα, a protein found on the surface of various tumour cells, including ovarian, endometrial, and lung cancers.
Its design allows for internalisation into FRα-expressing cells and the release of a bystander active topoisomerase-1 inhibitor (ZD06519), a new payload developed by Zymeworks to destroy tumour cells.
Zymeworks executive vice-president and chief medical officer Jeff Smith said: “Our team is excited to initiate this important clinical trial to assess the safety and tolerability of ZW191, our first antibody-drug conjugate utilising ZD06519, our novel proprietary payload, in patients with difficult-to-treat cancers.
“This global study represents a significant milestone in our mission to bring innovative and urgently needed therapies to patients in need.”
FRα is prevalent in around 70% of lung adenocarcinomas and 75% of high-grade serous ovarian carcinomas.
